Literature DB >> 3443600

Involvement of cholinergic nerves in excitatory junction potentials through prejunctional nicotinic receptors in the guinea-pig vas deferens.

Y Fukushi1, M Wakui.   

Abstract

1. The effects of various drugs on excitatory junction potentials (EJPs) elicited by field stimulation of the longitudinal smooth muscle of the guinea-pig vas deferens were examined using the sucrose-gap method. 2. Field stimulation with a single pulse (1.0 ms, 20 Vcm-1) produced a depolarization of 3-7 mV. When a single pulse was repetitively applied, the depolarization showed summation, resulting in action potential firing. 3. Tetrodotoxin (1 microM) and guanethidine (1 microM) completely suppressed EJPs whilst propranolol (1 microM) or atropine (0.1 microM) did not affect them. Phentolamine (1 microM) slightly potentiated EJPs. 4. d-Tubocurarine (dTC) at lower concentrations (0.5-2 microM) suppressed EJPs, but at a higher concentration (20 microM) the drug little affected them. 5. Hexamethonium (C6) suppressed EJPs at low concentrations (0.5-5 microM), but potentiated them at a higher concentration (50 microM). 6. Either dTC or C6, each at a concentration of 0.5 microM, did not affect the depolarization induced by exogenously applied ATP or noradrenaline. 7. These results suggest that in this tissue cholinergic nerve activity can contribute to the magnitude of EJPs, and that this effect is mediated through nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3443600     DOI: 10.1111/j.1474-8673.1987.tb00159.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  2 in total

1.  Prejunctional nicotinic receptors involved in facilitation of stimulation-evoked noradrenaline release from the vas deferens of the guinea-pig.

Authors:  L Todorov; K Windisch; H Shersen; A Lajtha; M Papasova; E S Vizi
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

2.  Effect of cleistanthin A and B on adrenergic and cholinergic receptors.

Authors:  S Parasuraman; R Raveendran
Journal:  Pharmacogn Mag       Date:  2011-07       Impact factor: 1.085

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.